Akut santral seröz koryoretinopatide potansiyel bir belirteç olarak trigliserit-glikoz indeksi

Yıl 2025, Cilt: 50 Sayı: 3, 586 - 593

Ali Osman Gündoğan , Naciye Tora , Selman Belviranlı , Mehmet Adam , Günhal Şatırtav , Refik Oltulu

https://doi.org/10.17826/cumj.1625502

Öz

Amaç: Bu çalışmada akut santral seröz koryoretinopatili (SSKR) hastalarda, kronik SSKR'de ve sağlıklı kontrollerde trigliserid-glukoz indeksi (TGI) düzeylerini karşılaştırmak ve TGI'nin akut SSKR riskini göstermedeki değerini değerlendirmek amaçlanmıştır.
Gereç ve Yöntem: Bu retrospektif çalışmaya 20 akut SSKR hastası, 20 kronik SSKR hastası ve 40 sağlıklı kontrol dahil edildi. TGİ, açlık plazma trigliseridler düzeyi ve açlık plazma glukozu kullanılarak hesaplandı ve değerler gruplar arasında karşılaştırıldı. Akut SSKR ve kontrol grupları arasında optimal TGI cut-off değerininin ve bu değerin sensitivite ve spesifitesinin hesaplanması için ROC eğrisi kullanıldı.
Bulgular: Gruplar arasında yaş ve cinsiyet açısından istatistiksel olarak anlamlı farklılık tespit edilmedi. TGI değeri kontrol grubunda 8.480.29, akut SSKR grubunda 8.910.34, kronik SSKR grubunda 8.590.40 olarak bulundu. (akut SSKR grubu ile kontrol grubu için p<0,001; kronik SSKR grubuna ile kontrol grubu için p=0,703; kronik SSKR grubuna ile akut SSKR grubu için p=0,011) Kontrol ve akut SSKR grupları arasında TGI için optimum ROC cutoff değeri %75 duyarlılık ve %85 özgüllük ile 8.74 olarak hesaplanmıştır. (AUC: 0.835, p<0.001, %95CI 0.719-0.951)
Sonuç: Akut SSKR hastalarında kardiyovasküler hastalıklar açısından dikkatli olunması gerektiğini göstermektedir. Ayrıca rutin kan analizi ile kolayca ölçülebilen bu biyobelirteç, SSKR’nin akut formuyla ilişkili potansiyel bir gösterge olabililir.

Anahtar Kelimeler

Santral Seröz Koryoretinopati , Trigliserid , Glukoz , Trigliserid-Glukoz İndeksi , Kan-Lipid Profili

Triglyceride-glucose index as a potential biomarker in acute central serous chorioretinopathy

Öz

Purpose: The aim of this study is to compare triglyceride-glucose index (TGI) levels in patients with acute central serous chorioretinopathy (CSCR), chronic CSCR, and healthy controls, and to the value of TGI in indicating the risk of acute CSCR.
Materials and Methods: This retrospective study included 20 patients with acute CSCR, 20 patients with chronic CSCR, and 40 healthy controls. The TGI was calculated using fasting plasma triglyceride and glucose levels, and values were compared between groups. A receiver operating characteristic (ROC) curve was used to calculate the optimal TGI cut-off value, sensitivity, and specificity between the acute CSCR and control groups.
Results: There were no statistically significant differences between the groups in terms of age and sex. The TGI value was 8.48±0.29 in the control group, 8.91±0.34 in the acute CSCR group, and 8.59±0.40 in the chronic CSCR group (p<0.001 for control vs. acute CSCR; p=0.703 for control vs. chronic CSCR; p=0.011 for acute vs. chronic CSCR). The optimal ROC cut-off value of TGI between the control and acute CSCR groups was calculated as 8.74 with 75% sensitivity and 85% specificity (AUC: 0.835, p<0.001, 95% CI 0.719-0.951).
Conclusion: Caution should be exercised in patients with acute CSCR regarding the presence of underlying cardiovascular disease. Additionally, this biomarker, which can be easily measured through routine blood testing, may serve as a potentia

Anahtar Kelimeler

Central Serous Chorioretinopathy , Triglyceride , Glucose , Triglyceride-Glucose Index , Blood-Lipid Profile

Kaynakça

• Wang M, Munch IC, Hasler PW, Prünte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol (Copenh). 2008;86:126 45.
• Gelber GS, Schatz H. Loss of vision due to central serous chorioretinopathy following psychological stress. Am J Psychiatry. 1987;144:46–50.
• Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology. 2008;115:169–73.
• Daruich A, Matet A, Behar-Cohen F. Central serous chorioretinopathy. Dev Ophthalmol. 2017;58:27–38.
• Sahoo NK, Govindhari V, Bedi R, Goud A, Singh R, Wu L et al. Subretinal hyperreflective material in central serous chorioretinopathy. Indian J Ophthalmol. 2020;68:126–29.
• Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015;48:82–118.
• Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc. 1986;84:799–845.
• Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S; Central Serous Chorioretinopathy Case-Control Study Group. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology. 2004;111:244–9.
• Chen SN, Chen YC, Lian I. Increased risk of coronary heart disease in male patients with central serous chorioretinopathy: Results of a population-based cohort study. Br. J. Ophthalmol. 2014;98:110–14.
• Tsai DC, Huang CC, Chen SJ, Chou P, Chung CM, Chan WL et al. Central serous chorioretinopathy and risk of ischaemic stroke: A population-based cohort study. Br. J. Ophthalmol. 2012;96:1484–88.
• Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, Voormolen JH et al. Mortality in patients treated for Cushing’s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab. 2007;92:976–81.
• Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6:299-304.
• Mao Q, Zhou D, Li Y, Wang Y, Xu SC, Zhao XH. The triglyceride-glucose index predicts coronary artery disease severity and cardiovascular outcomes in patients with non-st-segment elevation acute coronary syndrome. Dis Markers. 2019;2019:6891537.
• Park K, Ahn CW, Lee SB, Kang S, Nam JS, Lee BK et al. Elevated TyG index predicts progression of coronary artery calcification. Diabetes Care. 2019;42:1569-73.
• Aslan Sirakaya H, Sirakaya E. Association of triglyceride glucose index in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2024;262:2067-72.
• Neelam K, Aung KCY, Ang K, Tavintharan S, Sum CF, Lim SC. Association of triglyceride glucose index with prevalence and incidence of diabetic retinopathy in a singaporean population. Clin Ophthalmol. 2023;17:445-54.
• Thrall G, Lane D, Carroll D, Lip GY. A systematic review of the effects of acute psychological stress and physical activity on haemorheology, coagulation, fibrinolysis and platelet reactivity: implications for the pathogenesis of acute coronary syndromes. Thromb Res. 2007;120:819–47.
• Caccavale A, Imparato M, Romanazzi F, Negri A, Porta A, Ferentini F. A new strategy of treatment with low-dosage acetyl salicylic acid in patients affected by central serous chorioretinopathy. Med Hypotheses. 2009;73:435–7.
• Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology. 2003;110:698–703.
• Van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MT, Fliers E et al. Hypercoagulable state in Cushing’s syndrome: a systematic review. J Clin Endocrinol Metab. 2009;94:2743–50.
• Hsu HJ, Lee CY, Chao SC, Nien CW, Tzeng SH, Huang JY et al. The correlation of central serous chorioretinopathy and subsequent cardiovascular diseases of different types: a population-based cohort study. Int J Environ Res Public Health. 2019;16:5099. Published 2019 Dec 13.
• Tittl MK, Spaide RF, Wong D, Pilotto E, Yannuzzi LA et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol. 1999;128:63–8.
• Huang KH, Chen YH, Lee LC, Tai MC, Chung CH, Chen JT et al. Relationship between heart failure and central serous chorioretinopathy: A cohort study in Taiwan. J Chin Med Assoc. 2019;82:941-47.
• Iijima H, Iida T, Murayama K, Imai M, Gohdo T. Plasminogen activatorinhibitor 1 in central serous chorioretinopathy. Am J Ophthalmol. 1999;127:477–78.
• Böttiger C, Koch W, Lahn C, Mehilli J, von Beckerath N, Schömig A et al. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting. Am Heart J. 2003;146:855–61.
• Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689–97.
• Behar-Cohen F, Zhao M. Corticosteroids and the retina: a role for the mineralocorticoid receptor. Curr Opin Neurol. 2016;29:49–54.
• Wang L, Cong HL, Zhang JX, Hu YC, Wei A, Zhang YY et al. Triglyceride-glucose index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome. Cardiovasc Diabetol. 2020;19:80.
• Sirakaya HA, Ayyildiz B, Sert II, Kucuk B, Koca S, Sirakaya E. The role of triglyceride-glucose index in central retinal artery occlusion. Int Ophthalmol. 2025;45:82.
• Liu D, Yang K, Gu H, Li Z, Wang Y, Wang Y. Predictive effect of triglyceride-glucose index on clinical events in patients with acute ischemic stroke and type 2 diabetes mellitus. Cardiovasc Diabetol. 2022;21:280..